Laxmi Organic Industries (LXCHEM) Q1 24/25 earnings summary

Executive summary

• Strategy centers on cost and technology leadership, aiming for a top 5 global position and strong customer partnerships, with a diversified end-market exposure and ongoing expansion into new industries.

• Q1FY25 saw year-over-year growth, with Specialties segment driving performance and key Fluoro-intermediates assets at Lote now operational; construction at Dahej has commenced with regulatory approvals secured.

• Unaudited standalone and consolidated financial results for Q1 FY25 were approved with an unmodified opinion from statutory auditors.

Financial highlights

• Standalone revenue for Q1 FY25 was INR 7,296 million, up 4% year-on-year; standalone EBITDA at INR 941 million, up 15% year-on-year; standalone PAT at INR 463.11 million, up from INR 379.42 million in Q1 FY24.

• Consolidated revenue for Q1 FY25 was INR 7,301 million, flat year-on-year; consolidated PAT at INR 343.51 million, down from INR 383.29 million in Q1 FY24.

• Gross margin improved to 37.2% (standalone) and 36.6% (consolidated) in Q1FY25.

• Cash flow from operations at INR 80 crore for the quarter.

Outlook and guidance

• Ambition to double revenues and triple EBITDA by FY2028, with a CapEx plan of INR 11,000 million from FY2024 to FY2028, targeting a combined ROCE of 20%.

• Revenue from Dahej facility expected to start in FY2026, with peak revenues by FY2028; Fluoro assets at Lote expected to contribute from FY25.

• Conservative margin assumptions for essentials, with potential upside from new specialty products.